Due to her remarkable research efforts, Dr. Anna Orlova was awarded with the FFG Spin-Off Fellowship which enables her to form her own group within the Moriggl lab. In the course of the fellowship, Anna wants to target cancerous STAT5 oligomerization in Acute Myeloid Leukemia. We are impressed by this great accomplishment!
In the research work „The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease” Anna could show that hyperactivation of ERBB receptors and STAT3 can lead to transmission of tumours in the Tasmanian Devil. Congratulations, Anna!
For his excellent talk on “The gain-of-function STAT5BN642H mutation as a driver of T-cell lymphoma and leukemia”, PhD student Tobias Suske was honored with the Young Investigator Award at the Annual Meeting of the OeGHO & AHOP in Linz.
The project “Novel individualized therapies in JAK/STAT driven T cell malignancies” (Acronym: JAKSTAT-Target) aims to investigate the role of the JAK-STAT pathway in mature T cell lymphomas and to identify potential drugs and drug synergies targeting this pathway.
The consortium of six research groups from Vienna (Heidi Neubauer), Helsinki (Satu Mustjoki, Tero Aittokallio), Cologne (Marco Herling) and Toronto (Patrick Gunning, Benjamin Haibe-Kains) will focus on the entities of T cell prolymphocytic leukemia (T-PLL) and T cell large granular lymphocyte leukemia (T-LGLL), both showing a high incidence of missense mutations in JAK-STAT pathway genes.
The consortium, led by Satu Mustjoki, will uncover new mechanistic insights into these rare diseases and implement machine learning algorithms to predict synergistic effects from genomic, clinical and in vitro drug sensitivity data, ultimately integrating these data into clinical trials.
Anna Orlova had a productive research stay at the Hungarian Academy of Science in the group of Professor Keserü from the 11th till the 15th February 2019. On the 14th/15th February a conclusion meeting with Professor Moriggl, Dr. Bajusz and Mag. Ruckenbauer took place.
Richard, accompanied by Heidi and Tobi, enjoyed some days at the 2019’s Midwinter Conference in Tirol.
Besides presenting two posters at the event and extensively discussing recent topics in Immunology, they could also enjoy some winter sports in the beautiful Seefeld. Thank you for organising this unique and inspiring conference!
The project “ERANET-PLL – Implementation of (epi)genetic and metabolic networks in the targeting of T cell prolymphocytic leukemia” was funded within the European ERANET TRANSCAN-2 initiative (Horizon 2020).
The consortium consists of five research groups from Vienna (Richard Moriggl, Philipp Staber), Cologne (Marco Herling), Lyon (Emmanuel Bachy) and Dresden (Ingo Roeder). The consortium, led by Marco Herling, received €1,500,000 in funding, of which €304,720 was allocated to the group in Vienna.